B7-H3 NIR Imaging for Osteosarcoma Surgery
Phase 1
Recruiting
- Conditions
- OsteosarcomaB7-H3 ProbeResection MarginsLocal Recurrence
- Interventions
- Drug: a targeted probe B7H3-IRDye800CW
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06778603
- Locations
- 🇨🇳
Musculoskeletal Tumor Center, Beijing, Beijing, China
Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study
Not yet recruiting
- Conditions
- OsteosarcomaTranscriptomeTumor MicroenvironmentPrecision Medicine
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06776198
Dara-BCD for Rare MGRS
Phase 2
Not yet recruiting
- Conditions
- Monoclonal Gammopathy of Renal Significance (MGRS)
- Interventions
- Drug: Dara-CyBorD
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06771180
The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination
Not yet recruiting
- Conditions
- SarcomaBiomarkersProgression
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06751251
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
Not Applicable
Recruiting
- Conditions
- Gastrointestinal Stromal Tumor of StomachSubmucosal Tumor of Stomach
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06748690
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Endoscopic and Robotic NSM with Immediate Prosthesis Breast Reconstruction
Recruiting
- Conditions
- Nipple-sparing MastectomyImmediate Prosthesis ReconstructionEndoscopic SurgeryRobotic Surgery
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 484
- Registration Number
- NCT06748677
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Allo-HSCT vs ASCT in Adult T-LBL
Not Applicable
Not yet recruiting
- Conditions
- T Lymphoblastic Lymphoma
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 230
- Registration Number
- NCT06741813
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Recruiting
- Conditions
- Immune ThrombocytopeniaThrombotic Thrombocytopenic PurpuraHemophilia A, AcquiredDisseminated Intravascular CoagulationThrombophiliaDeep Vein ThrombosisPulmonary EmbolismThrombotic MicroangiopathiesCoagulation Factor DeficiencyHemophilia A
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06727669
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Department of Hematology, Beijing Hospital, Beijing, Beijing, China
Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery
Phase 1
Recruiting
- Conditions
- Breast CancerCollagen Protein
- Interventions
- Biological: Recombinant Humanized Type III Collagen Injection
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06725082
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Phase 2
Recruiting
- Conditions
- Osteosarcoma
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06714383
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China